b00n hat am 20.03.2012 - 17:54 folgendes geschrieben:

Quote

wb Vagnum, hast ja gerade volltreffer gelandet. smiley

yeah. guter Anfang, thanks. ROSG hat bei 1.00$ noch ein offenes Gap zu schliessen, vielleicht sieht man die katie noch höher irgendwann dieses Jahr. Offering war auch um 1.00$ herum.

Bist du noch drin bei TLON 0.70$? morgen ist ja das Panel. Hab ne 2te Zockerposi eingenomen. Was denkst du? bin mir bei TLON überhaupt nicht sicher....

gruess

b00n hat am 21.03.2012 - 17:15 folgendes geschrieben:

Quote

graz! Vagnum! 2ter treffer

jaa so machts spass. hab die Profitchen bei TLON mitgenommen.

PANEL Vote war : 7 ja 4 nein 2 enthaltung. May 13 2012 Zulassungstermin.

AFFY13.00$

Hat heute FDA Zulassung. Das Medi sollte Zugelassen werden, soeben gabs nen shaker von 14.00$ auf 10.74$ runter. Die Aktie hat ein Gesamtpreisziel von über 16$.

[Blocked Image: http://www.finviz.com/chart.ashx?t=AFFY&ty=c&ta=1&p=d&s=l]

AFFY 16.00$

Affymax Wins Approval of Drug for Anemic Kidney Patients

By Anna Edney on March 27, 2012

Affymax Inc. (AFFY) won U.S. approval for Omontys, an anemia-treatment competitor to Amgen Inc. (AMGN)medicines that have been the only option for patients with loss of kidney function for more than 20 years.

The Food and Drug Administration cleared Omontys, also known as peginesatide, for patients with chronic kidney disease on dialysis, according to a statement from the agency today. The treatment will be Palo Alto, California-based Affymax’s first marketed product.

Approval of the drug -- intended to be used once a month instead of as often as three times a week for Amgen’s Epogen -- may potentially save money for Medicare, the federal health program for the elderly and disabled. Peginesatide may generate as much as $700 million in peak sales by 2017, Ian Somaiya, an analyst at Piper Jaffray & Co. in New York, said in a telephone interview.

“We’re dealing with a monopoly right now and that’s not ideal because it’s occurred for two decades,” Somaiya said of Epogen. “Small and medium dialysis centers are price sensitive. Peginesatide would be the choice for these dialysis providers.”

Dialysis removes toxins from the blood when kidneys can’t.

Amgen’s Epogen, approved in 1989, generated $2 billion in sales last year, down 19 percent from 2010, according to data compiled by Bloomberg. Peginesatide may compete to a lesser extent with Thousand Oaks, California-based Amgen’s Aranesp, which is primarily used on non-dialysis kidney patients. Aranesp had $2.3 billion in sales last year.

JNJ’s Procrit Agreement

Johnson & Johnson’s Procrit is the same drug as Epogen though is used only in patients who aren’t undergoing dialysis under an agreement the New Brunswick, New Jersey-based drugmaker has with Amgen, Somaiya said.

Affymax has a profit-sharing agreement for peginesatide with Osaka, Japan-based Takeda Pharmaceutical Co. (4502)

Medicare spent $6.8 billion on dialysis and drugs for kidney failure patients in 2007, according to a March 2010 report from the U.S. Government Accountability Office, the investigative arm of Congress. Medicare, which covers almost everyone with kidney failure regardless of age, began reimbursing for such services in one bundled payment last year to save money.

DaVita Deal

Like peginesatide, Epogen is for anemia in chronic kidney disease patients on dialysis while Aranesp can also treat patients not on dialysis. The medicines are part of a class of drugs known as erythropoiesis-stimulating agents that boost production of red blood cells. The FDA recommended in June that doctors use the lowest possible doses of the agents because of potential heart risks. The agency in 2006 first warned that high doses of the anemia drugs may cause heart attacks and strokes.

Amgen, the world’s largest biotechnology company, has deals with the two largest dialysis providers DaVita Inc. (DVA) of Denver and Fresenius Medical Care AG (FME) in Bad Homburg, Germany. The deal with DaVita is exclusive and for seven years, while Fresenius’s agreement isn’t exclusive and is for an undisclosed amount of years.

To contact the reporter on this story: Anna Edney in Washington at aedney@bloomberg.net

To contact the editor responsible for this story: Reg Gale at rgale5@bloomberg.net

Das nenn ich mal nen fetten Anstieg die letzen Tage...

Rosetta Genomics Ltd
http://www.google.com/finance?q=ROSG

Hatten aber einen Split von 1:15 am 14.05.2012

samy hat am 24.05.2012 - 13:04 folgendes geschrieben:

Quote

Hatten aber einen Split von 1:15 am 14.05.2012

Und machen heute wieder satte 100%
http://www.google.com/finance?q=NASDAQ:ROSG

Ja wow hab es gesehen. Investiert?

Neostem NBS

..ist heiss, Kursvervielfacher ist möglich ... braucht einfach zeit, kaufen und liegenlassen

http://www.google.com/finance?q=AMEX:NBS

http://www.stockpickr.com/5-st…-1?puc=yahoo&cm_ven=YAHOO

PRESS RELEASE: NeoStem to Present at Three Investor Conferences in September
04.09.12 12:35:24- DJPN

NeoStem to Present at Three Investor Conferences in September 

  NEW YORK, Sept. 4, 2012 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NYSE MKT:NBS)
 ("NeoStem" or the "Company"), a rapidly emerging market leader in the fast
 growing cell therapy market, today announced that Company management will
 present at three investor conferences in September. 

  The 19th Annual Newsmakers in the Biotech Industry - BioCentury & Thomson
 Reuters 

   -- Date: September 7, 2012, 1:30 PM
 EDT - Venue: Millennium Broadway Hotel & Conference Center, New York, NY 

- Presenter: Robin L. Smith, M.D., M.B.A., Chairman and CEO of NeoStem 

  Rodman & Renshaw Annual Global Investment Conference 

   -- Date: September 10, 2012, 10:50 AM EDT 

 

   -- Venue: Waldorf Astoria, New York, NY 

 

   -- Presenter: Robin L. Smith, M.D., M.B.A., Chairman and CEO of NeoStem 

 

   -- A live webcast and 90-day archive of this presentation will be available 

      at http://wsw.com/webcast/rrshq22/nbs 

  National Investment Banking Association Conference 

   -- Date: September 13, 2012, 10:00 AM EDT 

 

   -- Venue: New York Marriott Downtown, New York, NY 

 

   -- Presenter: Robin L. Smith, M.D., M.B.A., Chairman and CEO of NeoStem 

  About NeoStem, Inc. 

  NeoStem, Inc. continues to develop and build on its core capabilities in cell
 therapy capitalizing on the paradigm shift that we see occurring in medicine.
 In particular, we anticipate that cell therapy will have a large role in the
 fight against chronic disease and in lessening the economic burden that these
 diseases pose to modern society. We are emerging as a technology and market
 leading company in this fast developing cell therapy market. Our multi-faceted
 business strategy combines a state-of-the-art contract development and
 manufacturing subsidiary, Progenitor Cell Therapy, LLC ("PCT") with a medically
 important cell therapy product development program, enabling near and long-term
 revenue growth opportunities. We believe this expertise and existing research
 capabilities and collaborations will enable us to achieve our mission of
 becoming a premier cell therapy company. 

  Our contract development and manufacturing service business supports the
 development of proprietary cell therapy products. NeoStem's most clinically
 advanced therapeutic, AMR-001, is being developed at Amorcyte, LLC
 ("Amorcyte"), which we acquired in October 2011. Amorcyte is developing a cell
 therapy for the treatment of cardiovascular disease and is enrolling patients
 in a Phase 2 trial to investigate AMR-001's efficacy in preserving heart
 function after a heart attack. Athelos Corporation ("Athelos"), which is
 approximately 80%-owned by our subsidiary, PCT, is collaborating with
 Becton-Dickinson in the early clinical exploration of a T-cell therapy for
 autoimmune conditions. In addition, pre-clinical assets include our VSEL(TM)
 Technology platform as well as our mesenchymal stem cells product candidate for
 regenerative medicine. Our service business and pipeline of proprietary cell
 therapy products work in concert, giving us a competitive advantage that we
 believe is unique to the biotechnology and pharmaceutical industries. Supported
 by an experienced scientific and business management team and a patent and
 patent pending (IP) portfolio, we believe we are well positioned to succeed. 

  Forward-Looking Statements for NeoStem, Inc. 

  This press release contains forward-looking statements within the meaning of
 the Private Securities Litigation Reform Act of 1995. Forward-looking
 statements reflect management's current expectations, as of the date of this
 press release, and involve certain risks and uncertainties. Forward-looking
 statements include statements herein with respect to the successful execution
 of the Company's business strategy, including with respect to the Company's or
 its partners' successful development of AMR-001 and other cell therapeutics,
 the size of the market for such products, its competitive position in such
 markets, the Company's ability to successfully penetrate such markets and the
 market for its CDMO business, and the efficacy of protection from its patent
 portfolio, as well as the future of the cell therapeutics industry in general,
 including the rate at which such industry may grow. Forward looking statements
 also include statements with respect to satisfying all conditions to closing
 the disposition of Erye, including receipt of all necessary regulatory
 approvals in the PRC. The Company's actual results could differ materially from
 those anticipated in these forward- looking statements as a result of various
 factors, including but not limited to (i) the Company's ability to manage its
 business despite operating losses and cash outflows, (ii) its ability to obtain
 sufficient capital or strategic business arrangement to fund its operations,
 including the clinical trials for AMR-001, (iii) successful results of the
 Company's clinical trials of AMR-001 and other cellular therapeutic products
 that may be pursued, (iv) demand for and market acceptance of AMR-001 or other
 cell therapies if clinical trials are successful and the Company is permitted
 to market such products, (v) establishment of a large global market for
 cellular-based products, (vi) the impact of competitive products and pricing,
 (vii) the impact of future scientific and medical developments, (viii) the
 Company's ability to obtain appropriate governmental licenses and approvals
 and, in general, future actions of regulatory bodies, including the FDA and
 foreign counterparts, (ix) reimbursement and rebate policies of government
 agencies and private payers, (x) the Company's ability to protect its
 intellectual property, (xi) the company's ability to successfully divest its
 interest in Erye, and (xii) matters described under the "Risk Factors" in the
 Company's Annual Report on Form 10-K filed with the Securities and Exchange
 Commission on March 20, 2012 and in the Company's other periodic filings with
 the Securities and Exchange Commission, all of which are available on its
 website. The Company does not undertake to update its forward-looking
 statements. The Company's further development is highly dependent on future
 medical and research developments and market acceptance, which is outside its
 control. 

CONTACT: Trout Group 

         Gitanjali Jain Ogawa, Vice President 

         Phone: +1-646-378-2949 

         Email: gogawa@troutgroup.com 

  (END) Dow Jones Newswires

  04-09-12 1135GMT

Neostem (US6406503051)

Industries
Biotechnology

CYCC 8.00$

Cyclacel Pharmaceuticals Inc. : Cyclacel to Report New Sapacitabine Clinical Data at the American Society of Hematology Annual Meeting

12/04/2012| 09:47am US/Eastern

BERKELEY HEIGHTS, N.J., Dec. 4, 2012 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders announced today that updated Phase 3 clinical trial results for the treatment of elderly patients with newly diagnosed acute myeloid leukemia (AML) treated with sapacitabine and decitabine administered in alternating cycles will be presented at a poster presentation during the 54th Annual Meeting of the American Society of Hematology (ASH) in Atlanta, on Sunday, December 9, 2012.

The poster's abstract details are as follows:

About Cyclacel Pharmaceuticals, Inc.

Cyclacel is a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases. The Company's most advanced oral product candidate, sapacitabine, is the subject of SEAMLESS, a Phase 3 trial being conducted under an SPA with the FDA as front-line treatment of acute myeloid leukemia (AML) in the elderly and Phase 2 studies for AML, myelodysplastic syndromes (MDS), chronic lymphocytic leukemia (CLL) and solid tumors including breast, lung, ovarian and pancreatic cancer. Cyclacel's pipeline includes seliciclib, a CDK inhibitor, in Phase 2 for lung and nasopharyngeal cancer and in Phase 1 in combination with sapacitabine; and CYC065, a second generation CDK inhibitor, in IND-directed development. Cyclacel's strategy is to build a diversified biopharmaceutical business focused in hematology and oncology based on a development pipeline of novel drug candidates. Please visit www.cyclacel.com for additional information.

bit.ly/SNwKZ6

[Blocked Image: http://www.finviz.com/chart.ashx?t=CYCC&ty=c&ta=1&p=d&s=l]